Identification and Characterization of RK22, a Novel Antimicrobial Peptide from Hirudinaria manillensis against Methicillin Resistant Staphylococcus aureus
Lu X, Yang M, Zhou S, Yang S, Chen X, Khalid M, Wang K, Fang Y, Wang C, Lai R, Duan Z (2023) · International Journal of Molecular Sciences
Study Profile
- Model / material
- bioinformatic discovery and synthesis of a novel antimicrobial peptide (RK22) from Hirudinaria manillensis salivary-gland transcriptome, followed by in-vitro and in-vivo antimicrobial assays against methicillin-resistant Staphylococcus aureus (MRSA); Kunming Institute of Zoology, Chinese Academy of Sciences
- Method
- Synthetic RK22 peptide administered against MRSA in-vitro (MIC determination, biofilm assays) and in-vivo (mouse model)
- Main result
- RK22 showed potent anti-MRSA activity (MIC 6.25 μg/mL) including clinically resistant strain; rapid bacterial killing; inhibited biofilm formation and promoted biofilm eradication; good plasma stability; negligible cytotoxicity; minimal hemolysis; no significant pro-coagulation effects; in-vivo administration significantly inhibited MRSA infection
- PMID
- 37686259
Key Findings
- Novel RK22 antimicrobial peptide identified from H. manillensis salivary gland transcriptome
- Potent anti-MRSA activity (MIC 6.25 μg/mL) including clinically resistant strains
- Biofilm inhibition and eradication — relevant to chronic-wound and indwelling-device infections
- Good safety profile (low cytotoxicity, minimal hemolysis, no pro-coagulation)
- In-vivo mouse efficacy demonstrated — supports advancing to GLP-toxicology and Phase-I evaluation
Limitations
- Preclinical (in-vitro + mouse) — no human data
- Mouse model does not capture all clinical complexity of MRSA disease
- Long-term toxicology, pharmacokinetics, and immunogenicity not characterized
- Resistance development potential not yet studied
- Hirudinaria manillensis is not the K040187-cleared device leech
Clinical Implications
Lu 2023 illustrates how underrepresented Asian medicinal-leech sialotranscriptomes can yield translational antimicrobial drug candidates with activity against MDR pathogens. For ASH, the study underscores that leech-pharmacology is a deep biodiversity reservoir extending beyond the established hirudin literature. No US K040187 clinical-practice implications; relevant to translational antimicrobial drug discovery.
Related studies
Genetic Variation and Gene Expression of the Antimicrobial Peptide Macins in Asian Buffalo Leech (Hirudinaria manillensis)
Yu Y, Tang L, Xiao M, Yin J, Ye T, Sun R, Ai R, Zhao F, Huang Z, Lin G (2025)
Comparative genomics suggests extensive antithrombotic gene expansion in Haemadipsa yanyuanensis
Lin Y, Zhao F, Fan S, Yang D, Tong X, Tang L, Kong D, Lin G, Liu Z (2025)
Analysis of antibiotic resistant infections associated with hirudotherapy
Brauer PR, Saadah M, Fritz MA, Wu SS, Lamarre ED (2024)
Molecular Insights into Leech-Derived Bioactive Compounds: Biochemical Mechanisms and Therapeutic Potential
Raghavi S, Deva Darshini B, Saravanan KM, Anbarasu K (2026)